Innocan Pharma Corporation has announced the entering into of a wide-scope commercial distribution agreement with UAB Medexy (UAB Medexy).

As part of the multi-year Distribution Agreement, UAB Medexy has an exclusive right to distribute both of Innocan's SHIR and RELIEF&GO brands in Lithuania, Latvia & Estonia, based on an agreed purchase forecast.

UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products.

UAB Medexy has a reputation as a key Eastern European player in the import and distribution of cosmetic products and medical devices. It has been very active in the Lithuanian dermo-cosmetics market for the past 17 years, positioning it as one of the major players in its industry.

"We are very excited to distribute Innocan Pharma's products", Vidmantas Lozys, UAB Medexy CEO, "We firmly believe that SHIR™ Facial Care will be very well received by our customers, and we assume that this will be an exemplary success story for everyone involved."

Iris Bincovich, CEO of InnoCan stated that "We are humbled to have a leading European market leader such as UAB Medexy as our market-partner in Lithuania, Latvia & Estonia. This new business will complement both Innocan's exponential growth strategy and UAB Medexy Health and Beauty market strategy."